Product Code: ETC6186308 | Publication Date: Sep 2024 | Updated Date: Apr 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The non-cystic fibrosis bronchiectasis market in Australia is expanding due to increased diagnosis rates and improved access to healthcare. Pharmaceutical companies are focusing on developing effective treatments, including antibiotics, bronchodilators, and airway clearance therapies. Government support for respiratory health programs is also driving market growth.
The non-cystic fibrosis bronchiectasis market in Australia is growing due to increasing prevalence of respiratory diseases and rising demand for effective treatment options. Growing adoption of antibiotics, mucolytics, and bronchodilators for managing symptoms, along with increasing investment in research and development of targeted therapies, are driving market growth. Rising awareness about lung health and increasing government funding for respiratory disease management are also contributing to market expansion.
The non-cystic fibrosis bronchiectasis market in Australia faces challenges due to the complexity of diagnosis and limited awareness among healthcare providers. High costs of treatment and limited availability of targeted therapies restrict patient access. Regulatory hurdles for drug approval and slow reimbursement processes further limit market penetration. Competition from alternative respiratory treatments and limited clinical trials add to the market`s difficulties.
The non-cystic fibrosis bronchiectasis market in Australia is growing due to increased awareness and improved diagnostic capabilities for this chronic lung condition. Investment opportunities lie in developing new inhalation therapies, improving access to diagnostic tools, and expanding respiratory care centers. Growth in the aging population and increased prevalence of respiratory diseases are supporting market expansion.
Non-cystic fibrosis bronchiectasis treatments, including antibiotics and inhaled therapies, are regulated by the TGA. Approved medications are listed on the Pharmaceutical Benefits Scheme (PBS) for subsidized access. The government supports research into respiratory diseases through the MRFF. Import and export of bronchiectasis drugs are controlled under pharmaceutical trade agreements. Public health initiatives promote early diagnosis and management of bronchiectasis.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Non-Cystic Fibrosis Bronchiectasis Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Non-Cystic Fibrosis Bronchiectasis Market - Industry Life Cycle |
3.4 Australia Non-Cystic Fibrosis Bronchiectasis Market - Porter's Five Forces |
3.5 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.6 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.7 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.8 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Non-Cystic Fibrosis Bronchiectasis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Australia Non-Cystic Fibrosis Bronchiectasis Market Trends |
6 Australia Non-Cystic Fibrosis Bronchiectasis Market, By Types |
6.1 Australia Non-Cystic Fibrosis Bronchiectasis Market, By Treatment |
6.1.1 Overview and Analysis |
6.1.2 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Treatment, 2021- 2031F |
6.1.3 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Surgery, 2021- 2031F |
6.1.4 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By physiotherapy, 2021- 2031F |
6.1.5 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By vaccination, 2021- 2031F |
6.1.6 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Airway pharmacotherapy, 2021- 2031F |
6.1.7 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Antibiotics, 2021- 2031F |
6.1.8 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Australia Non-Cystic Fibrosis Bronchiectasis Market, By Type |
6.2.1 Overview and Analysis |
6.2.2 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Oral, 2021- 2031F |
6.2.3 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.2.4 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Australia Non-Cystic Fibrosis Bronchiectasis Market, By Diagnosis |
6.3.1 Overview and Analysis |
6.3.2 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By CT scan, 2021- 2031F |
6.3.3 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Bronchoscopy, 2021- 2031F |
6.3.4 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Chest X-ray, 2021- 2031F |
6.3.5 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Sputum Culture Test, 2021- 2031F |
6.3.6 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Blood Tests, 2021- 2031F |
6.3.7 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Australia Non-Cystic Fibrosis Bronchiectasis Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Clinic, 2021- 2031F |
6.4.3 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Hospital, 2021- 2031F |
6.4.4 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Australia Non-Cystic Fibrosis Bronchiectasis Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
7 Australia Non-Cystic Fibrosis Bronchiectasis Market Import-Export Trade Statistics |
7.1 Australia Non-Cystic Fibrosis Bronchiectasis Market Export to Major Countries |
7.2 Australia Non-Cystic Fibrosis Bronchiectasis Market Imports from Major Countries |
8 Australia Non-Cystic Fibrosis Bronchiectasis Market Key Performance Indicators |
9 Australia Non-Cystic Fibrosis Bronchiectasis Market - Opportunity Assessment |
9.1 Australia Non-Cystic Fibrosis Bronchiectasis Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.2 Australia Non-Cystic Fibrosis Bronchiectasis Market Opportunity Assessment, By Type, 2021 & 2031F |
9.3 Australia Non-Cystic Fibrosis Bronchiectasis Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
9.4 Australia Non-Cystic Fibrosis Bronchiectasis Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 Australia Non-Cystic Fibrosis Bronchiectasis Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Non-Cystic Fibrosis Bronchiectasis Market - Competitive Landscape |
10.1 Australia Non-Cystic Fibrosis Bronchiectasis Market Revenue Share, By Companies, 2024 |
10.2 Australia Non-Cystic Fibrosis Bronchiectasis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |